References

  1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–3141.
  2. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679–687 e1.
  3. Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol. 2013;62(8):697–703.
  4. Sui X, Church TS, Meriwether RA, et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57(6):845–852.
  5. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: An active component or an innocent bystander? Metabolism. 2006;55(10):1293–1301.
  6. Ryu S, Song J, Choi BY, et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann Epidemiol. 2007;17(4):245–252.
  7. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120(5):442–447.
  8. Lee JM, Kim HC, Cho HM, et al. Association between serum uric acid level and metabolic syndrome. J Prev Med Public Health. 2012;45(3):181–187.
  9. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007;115(19):2526–2532.
  10. Yang T, Chu CH, Bai CH, et al. Uric acid level as a risk marker for metabolic syndrome: A Chinese cohort study. Atherosclerosis. 2012;220(2):525–531.
  11. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels—the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford). 2008;47(5):713–717.
  12. Bedir A, Topbas M, Tanyeri F, et al. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J. 2003;44(4):527–536.
  13. Nakagawa T, Tuttle KR, Short RA, et al. Hypothesis: Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1(2):80–86.
  14. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60(4):1258–1269.
  15. Rho YH, Zhu Y, Choi HK. The epidemiology of uric acid and fructose. Semin Nephrol. 2011;31(5):410–419.
  16. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625–F631.
  17. Krishnan E, Akhras KS, Sharma H, et al. Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM. 2013;106(8):721–729.
  18. Dehghan A, van Hoek M, Sijbrands EJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31(2):361–362.
  19. Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: A prospective study. Am J Med. 2010;123(10):957–961.
  20. Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: A 15-year follow-up study. Am J Epidemiol. 2012;176(2):108–116.
  21. Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18(6):523–530.
  22. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47(10):1567–1570.
  23. Bruderer SG, Bodmer M, Jick SS, Meier CR. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: A population-based case-control study. Ann Rheum Dis. 2014 Apr. 12;[Epub ahead of print].
  24. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: Time to start. Nat Rev Drug Discov. 2014;13(6):465–476.
  25. Vitale A, Cantarini L, Rigante D, et al. Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol. 2014 Apr. 15;[Epub ahead of print].
  26. Choi HK, Zhang Y. Bariatric surgery as urate-lowering therapy in severe obesity. Ann Rheum Dis. 2014;73(5):791–793.
  27. Juraschek SP, Miller ER 3rd, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 1988–1994 and 2007–2010. Arthritis Care Res (Hoboken). 2013;65(1):127–132.
  28. Maynard JW, McAdams DeMarco MA, Baer AN, et al. Incident gout in women and association with obesity in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Med. 2012;125(7):717 e9–717 e17.
  29. DeMarco MA, Maynard JW, Huizinga MM, et al. Obesity and younger age at gout onset in a community-based cohort. Arthritis Care Res (Hoboken). 2011;63(8):1108–1114.
  30. Oyama C, Takahashi T, Oyamada M, et al. Serum uric acid as an obesity-related indicator in early adolescence. Tohoku J Exp Med. 2006;209(3):257–262.
  31. Kim TH, Lee SS, Yoo JH, et al. The relationship between the regional abdominal adipose tissue distribution and the serum uric acid levels in people with type 2 diabetes mellitus. Diabetol Metab Syndr. 2012;4(1):3.
  32. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The health professionals follow-up study. Arch Intern Med. 2005;165(7):742–748.
  33. Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: A prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797–802.
  34. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–2693.
  35. Dalbeth N, Pool B, Yip S, et al. Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: A prospective study. Ann Rheum Dis. 2013;72(9):1583–1584.

Share: